Respiratory failure due to choriocarcinoma: a study of 103 dyspneic patients.
Treatment of choriocarcinoma is mostly successful but there is still appreciable mortality from early respiratory failure. A series of 135 patients with choriocarcinoma presenting with dyspnea between 1960 and 1988 was studied to find prognostic factors for early respiratory death and to identify how mortality may be further reduced. Mortality with respect to early respiratory death (ERD) was 11% and was significantly associated with WHO prognostic score, chest X-ray appearance, central cyanosis, tachycardia, anemia, and clinical evidence of pulmonary hypertension. Indicators on chest X ray of high risk of ERD were the presence of more than 10 opacities, extensive opacification of lung fields, size of metastases, and hazy background obscuring the vascular pattern. Intensity of initial treatment was not correlated with this outcome. A set of criteria has been derived which will predict ERD with 100% sensitivity and 38% positive predictive value. These are opacification of lung fields on chest X ray of more than 50%, OR initial plasma hCG level greater than 10(5) when there is anemia and a history of chest pain. Patients presenting with choriocarcinoma and dyspnea who fulfill these criteria should be considered for extracorporeal perfusion techniques. As respiratory failure in this condition is characterized by hypoxemia and right-to-left shunting, extracorporeal perfusion should be effective. Ventilation should be avoided as no patient survived mechanical ventilation.
Kelly
M P
MP
Department of Medical Oncology, Charing Cross Hospital, London, United Kingdom.
Rustin
G J
GJ
Ivory
C
C
Phillips
P
P
Bagshawe
K D
KD
D000328:Adult; D000740:Anemia / Q000401:mortality; D001784:Blood Gas Analysis; D002822:Choriocarcinoma / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D003490:Cyanosis / Q000401:mortality; D003609:Dactinomycin; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000209:etiology*; D005047:Etoposide; D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000401:mortality; D008168:Lung / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000556:secondary; D008727:Methotrexate; D011247:Pregnancy; D011859:Radiography; D012131:Respiratory Insufficiency / Q000209:etiology*; D012307:Risk Factors; D013610:Tachycardia / Q000401:mortality; D014594:Uterine Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000401:mortality
D003609:Dactinomycin; D005047:Etoposide; D008727:Methotrexate